tert-butyl (4-nitrophenyl) pentane-1,5-diyldicarbamate | 1202571-40-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (4-nitrophenyl) pentane-1,5-diyldicarbamate
• 英文别名: Tert-butyl 5-((4-nitrophenoxy)carbonylamino)pentylcarbamate；(4-nitrophenyl) N-[5-[(2-methylpropan-2-yl)oxycarbonylamino]pentyl]carbamate
• CAS: 1202571-40-1
• 化学式: C₁₇H₂₅N₃O₆
• 分子量: 367.402
• InChiKey: HPMSLBXWSFREDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-nitrophenyl) pentane-1,5-diyldicarbamate 、 O-cyclohexyl-hydroxylamine 在 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  [EN] SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE
  [FR] DÉRIVÉS DE L'ACIDE SQUARIQUE UTILISÉS COMME INHIBITEURS DU NICOTINAMIDE

  摘要：

  本申请公开了公式A的新颖方酸衍生物：来自-C(=O)-，-S(=O)2-，-C(=S)-和-P(=O)(R5)-；B：-，-O-，-NR6-和-C(=O)-NR6-；D：-，-O-，-CR7R8-和-NR9；m=0-12；n=0-12；m+n=1-20；p=0-2；R1：杂环烷基，芳基；R2：H，C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；R3：C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；或R2和R3：含氮杂环/杂芳环；R4和R4*：H，C1-12-烷基，C1-12-烯基；以及其药学上可接受的盐和前药，以及它们在治疗由NAMPRT水平升高引起的疾病/症状中的用途（炎症和组织修复紊乱，特别是类风湿关节炎，炎症性肠病，哮喘和CPOD，骨关节炎，骨质疏松症和纤维化疾病；皮肤病；自身免疫疾病，包括系统性红斑狼疮，多发性硬化，银屑病性关节炎，强直性脊柱炎，组织和器官排斥，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱，与感染和病毒感染相关的炎症，成人呼吸窘迫综合征，遗传性毛细血管扩张症）。

  公开号：

  WO2009156421A1
• 作为产物：
  描述：

  N-(5-氨基戊基)氨基甲酸叔丁酯 、 对硝基苯基氯甲酸酯 在 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 为溶剂， 生成 tert-butyl (4-nitrophenyl) pentane-1,5-diyldicarbamate
  参考文献：
  名称：

  [EN] SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE
  [FR] DÉRIVÉS DE L'ACIDE SQUARIQUE UTILISÉS COMME INHIBITEURS DU NICOTINAMIDE

  摘要：

  本申请公开了公式A的新颖方酸衍生物：来自-C(=O)-，-S(=O)2-，-C(=S)-和-P(=O)(R5)-；B：-，-O-，-NR6-和-C(=O)-NR6-；D：-，-O-，-CR7R8-和-NR9；m=0-12；n=0-12；m+n=1-20；p=0-2；R1：杂环烷基，芳基；R2：H，C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；R3：C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；或R2和R3：含氮杂环/杂芳环；R4和R4*：H，C1-12-烷基，C1-12-烯基；以及其药学上可接受的盐和前药，以及它们在治疗由NAMPRT水平升高引起的疾病/症状中的用途（炎症和组织修复紊乱，特别是类风湿关节炎，炎症性肠病，哮喘和CPOD，骨关节炎，骨质疏松症和纤维化疾病；皮肤病；自身免疫疾病，包括系统性红斑狼疮，多发性硬化，银屑病性关节炎，强直性脊柱炎，组织和器官排斥，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱，与感染和病毒感染相关的炎症，成人呼吸窘迫综合征，遗传性毛细血管扩张症）。

  公开号：

  WO2009156421A1

文献信息

• [EN] NOVEL UREA AND THIOUREA DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'URÉE ET DE THIOURÉE
  申请人：TOPOTARGET AS

  公开号：WO2010023307A1

  公开（公告）日：2010-03-04

  The present application discloses compounds of formula (I) wherein X is =O, =S, =NH, =NOH and =NO-Me; A is -C(=O)-, -S(=O)2 -, -C(=S)- and P(=O)(R5)-; B is, -O-, -(CH2) 3-6-, and O-(CH2)2-5-; D is, -O-, -CR7R8 -and -NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

  本申请公开了以下式(I)的化合物，其中X为=O、=S、=NH、=NOH和=NO-Me；A为-C(=O)-、-S(=O)2-、-C(=S)-和P(=O)(R5)-；B为-O-、-(CH2)3-6-和O-( )2-5-；D为-O-、-CR7R8-和-NR9；m为0-12，n为0-12，m+n为1-20；p为0-4；R1为opt.sub.杂环烷基；以及其药学上可接受的盐和前药。该申请还公开了该化合物用作治疗由尼克酰胺磷酸核糖转移酶(NAMPRT)水平升高引起的疾病或症状的药物，例如炎症和组织修复紊乱；皮肤病；自身免疫疾病，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱症，与感染相关的炎症和某些病毒感染，包括获得性免疫缺陷综合症（AIDS），成人呼吸窘迫综合征，遗传性共济失调。
• SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE
  申请人：Christensen Mette Knak

  公开号：US20120225847A1

  公开（公告）日：2012-09-06

  The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O) 2 —, —C(═S)— and —P(═O)(R 5 )—; B: -, —O—, —NR 6 — and —C(═O)—NR 6 —; D: -, —O—, —CR 7 R 8 — and —NR 9 ; m=0-12; n=0-12; m+n=1-20; p=0-2; R 1 : heteroaryl, aryl; R 2 : H, C 1-12 -alkyl, C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 —(C 1-6 -alkyl), C 1-12 -alkenyl, aryl, heterocyclyl, heteroaryl; R 3 : C 1-12 -alkyl, C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 —(C 1-6 -alkyl), C 1-12 -alkenyl, aryl, heterocyclyl, heteroaryl; or R 2 and R 3 : N-containing heterocyclic/heteroaromatic ring; R 4 and R 4 *: H, C 1-12 -alkyl, C 1-12 -alkenyl; and pharmaceutically acceptable salts and prodrugs thereof, and their use in the treatment of diseases/conditions caused by an elevated level of NAMPRT (inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD, osteoarthritis, osteoporosis and fibrotic diseases; dermatosis; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and viral infections, adult respiratory distress syndrome, ataxia telengiectasia).

  本申请公开了公式A的新型苯二甲酸衍生物：从—C（═O）—，—S（═O）2—，—C（═S）—和—P（═O）（R5）—；B：-，—O—，—NR6—和—C（═O）—NR6—；D：-，—O—，—CR7R8—和—NR9；m=0-12；n=0-12；m+n=1-20；p=0-2；R1：杂环芳基，芳基；R2：H，C1-12-烷基，C3-12-环烷基，—[CH2CH2O]1-10—（C1-6-烷基），C1-12-烯基，芳基，杂环烷基，杂环芳基；R3：C1-12-烷基，C3-12-环烷基，—[CH2CH2O]1-10—（C1-6-烷基），C1-12-烯基，芳基，杂环烷基，杂环芳基；或R2和R3：含氮杂环/杂芳基环；R4和R4*：H，C1-12-烷基，C1-12-烯基；以及其药学上可接受的盐和前药，以及它们在治疗由NAMPRT水平升高引起的疾病/状况中的用途（炎症和组织修复障碍，特别是类风湿性关节炎，炎症性肠病，哮喘和CPOD，骨关节炎，骨质疏松症和纤维性疾病；皮肤病；自身免疫性疾病，包括系统性红斑狼疮，多发性硬化症，银屑病性关节炎，强直性脊柱炎，组织和器官排斥，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，消瘦症，与感染和病毒感染相关的炎症，成人呼吸窘迫综合征，遗传性毛细血管扩张性共济失调）。
• Squaric acid derivatives as inhibitors of the nicotinamide
  申请人：Christensen Mette Knak

  公开号：US09006426B2

  公开（公告）日：2015-04-14

  The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O)2—, —C(═S)— and —P(═O)(R5)—; B: -, —O—, —NR6— and —C(═O)—NR6—; D: -, —O—, —CR7R8— and —NR9; m=0-12; n=0-12; m+n=1-20; p=0-2; R1: heteroaryl, aryl; R2: H, C1-12-alkyl, C3-12-cycloalkyl, —[CH2CH2O]1-10—(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, heteroaryl; R3: C1-12-alkyl, C3-12-cycloalkyl, —[CH2CH2O]1-10—(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, heteroaryl; or R2 and R3: N-containing heterocyclic/heteroaromatic ring; R4 and R4*: H, C1-12-alkyl, C1-12-alkenyl; and pharmaceutically acceptable salts and prodrugs thereof, and their use in the treatment of diseases/conditions caused by an elevated level of NAMPRT (inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD, osteoarthritis, osteoporosis and fibrotic diseases; dermatosis; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and viral infections, adult respiratory distress syndrome, ataxia telengiectasia).

  本申请公开了新型苯二甲酸衍生物的化学式A：从—C（═O）—，—S（═O）2—，—C（═S）—和—P（═O）（R5）—; B：-，—O—，—NR6—和—C（═O）—NR6—; D：-，—O—，—CR7R8—和—NR9; m=0-12; n=0-12; m+n=1-20; p=0-2; R1：杂环芳基，芳基; R2：H，C1-12-烷基，C3-12-环烷基，—[CH2CH2O]1-10—（C1-6-烷基），C1-12-烯基，芳基，杂环芳基，杂环芳基; R3：C1-12-烷基，C3-12-环烷基，—[CH2CH2O]1-10—（C1-6-烷基），C1-12-烯基，芳基，杂环芳基，杂环芳基; 或R2和R3：含氮杂环/杂芳烷环; R4和R4 *：H，C1-12-烷基，C1-12-烯基; 以及其药学上可接受的盐和前药，以及它们在治疗由NAMPRT水平升高引起的疾病/症状中的应用（炎症和组织修复障碍，尤其是类风湿性关节炎，炎症性肠病，哮喘和CPOD，骨关节炎，骨质疏松症和纤维病; 皮肤病; 自身免疫性疾病，包括系统性红斑狼疮，多发性硬化症，银屑病性关节炎，强直性脊柱炎，组织和器官排斥，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，消瘦症，与感染和病毒感染相关的炎症，成人呼吸窘迫综合征，遗传性毛细血管扩张性萎缩症）。
• Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness
  作者：Aparna Sundaram、Chun Chen、Nilgun Isik Reed、Sean Liu、Seul Ki Yeon、Joel McIntosh、You-Zhi Tang、Hyunjun Yang、Marc Adler、Richard Beresis、Ian B. Seiple、Dean Sheppard、William F. DeGrado、Hyunil Jo

  DOI：10.1016/j.bmcl.2020.127578

  日期：2020.11

  Inhibition of integrin α5β1 emerges as a novel therapeutic option to block transmission of contractile forces during asthma attack. We designed and synthesized novel inhibitors of integrin α5β1 by backbone replacement of known αvβ1 integrin inhibitors. These integrin α5β1 inhibitors also retain the nanomolar potency against αvβ1 integrin, which shows promise for developing dual integrin α5β1/αvβ1 inhibitor. Introduction of hydrophobic adamantane group significantly boosted the potency as well as selectivity over integrin αvβ3. We also demonstrated one of the inhibitors (11) reduced airway hyperresponsiveness in ex vivo mouse tracheal ring assay. Results from this study will help guide further development of integrin α5β1 inhibitors as potential novel asthma therapeutics.
• NOVEL UREA AND THIOUREA DERIVATIVES
  申请人：Christensen Mette Knak

  公开号：US20120010172A1

  公开（公告）日：2012-01-12

  The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O) 2 —, —C(═S)— and P(═O)(R 5 )—; B is, —O—, —(CH 2 ) 3-6 —, and O—(CH 2 ) 2-5 —; D is, —O—, —CR 7 R 8 — and —NR 9 ; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R 1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.